Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial
Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...
Assembly Bio spikes after early-stage data for Gilead-partnered Hep B therapy
Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher in the premarket on Thursday after the antiviral developer posted ...
What to expect from RFK Jr. in 2025
In the spirit of the season, the Washington Examiner has identified 12 issues we believe will shape and influence 2025 and ...